Moolec Science (MLEC) Income from Continuing Operations (2022 - 2024)
Moolec Science (MLEC) reported Income from Continuing Operations of 2146418.0 for Q4 2024, down 6.28% on a YoY basis from 2290349.43 in Q1 2024, and down 10.44% sequentially from 1943488.0 in Q3 2024.
Moolec Science (MLEC) Income from Continuing Operations (2022 - 2024) Analysis & Trends
Moolec Science (MLEC) has 3 years of Income from Continuing Operations data on file, last reported at 2146418.0 in Q4 2024.
- For the quarter ending Q4 2024, Income from Continuing Operations fell 6.28% year-over-year to 2146418.0; the trailing twelve-month figure through Dec 2024 stood at 8623350.0 (down 20.32% YoY), and the FY2024 full-year result was 8359245.0, up 83.93% from the prior year.
- Income from Continuing Operations retreated to 2146418.0 in Q4 2024, from 1943488.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 358578.0 in Q1 2023 to a low of 47960848.0 in Q4 2022.
- A 3-year average of 5596522.58 and a median of 1874891.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 95.79% in 2023 and slumped 255.65% in 2024, its largest moves.
- Tracing MLEC's Income from Continuing Operations over 3 years: stood at 47960848.0 in 2022, then surged by 95.79% to 2019507.0 in 2023, then decreased by 6.28% to 2146418.0 in 2024.
- Business Quant data shows MLEC's Income from Continuing Operations at 2146418.0 in Q4 2024, 1943488.0 in Q3 2024, and 3258165.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.15 Mn |
| Sep 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -3.26 Mn |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Sep 30, 2023 | -1.81 Mn |
| Jun 30, 2023 | -2.98 Mn |
| Mar 31, 2023 | -358,578.00 |
| Dec 31, 2022 | -47.96 Mn |
| Sep 30, 2022 | -721,426.00 |
| Jun 30, 2022 | -1.52 Mn |
| Mar 31, 2022 | -1.17 Mn |